Enlivex Therapeutics Ltd.
POB 12167 Hadassah Ein Kerem
Jerusalem
91120
Tel: 972-2-6778753
Fax: 972-2-5722071
Website: http://www.enlivexpharm.com/
Email: general@enlivexpharm.com
129 articles about Enlivex Therapeutics Ltd.
-
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
2/16/2021
Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,927,343 covering Allocetra TM , the company’s immunotherapy product candidate. The new patent is expected to provide added intellectual property protec
-
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
2/12/2021
Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions. H.C. Wainwrigh
-
Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
2/10/2021
Enlivex Therapeutics Ltd. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.
-
Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
2/9/2021
Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 500,000 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per share.
-
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
2/3/2021
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today reported positive top-line results from a multi-center, investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients
-
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
12/7/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carrying a patent number ZL201380071109.8.
-
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
12/3/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of an investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients.
-
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
11/18/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported a positive two-year clinical outcome following the first Allocetra™ treatment of a hospitalized patient with erosive osteoarthritis, a rare bone disease, which has no approved nor effective treatment options and typically involves rapid destruction of hip and shoulder bones.
-
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
11/17/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that Brian Schwartz, MD, who served for twelve years as Chief Medical Officer of ArQule, Inc. and led ArQule’s research and development programs through its $2.7 billion acquisition by Merck earlier this year, joined the Enlivex Board of Directors on November, 15, 2020.
-
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
11/11/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference.
-
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy
11/5/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering methods of using Allocetra™, the company’s immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases com
-
BioSpace Global Roundup, Nov. 5
11/5/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
11/3/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed Company-sponsored Phase IIb clinical trial evaluating Allocetra ™ , in sepsis patients. The planned Company-sponsored Phase IIb clinical trial is a multi-center, randomized, placebo-controlled study, which is expected to recruit up to 160 sepsis patients
-
Enlivex to Host COVID-19 Webinar: The Staging of a New Disease and Its Implications for Treatment Options, with Mount Sinai Key Opinion Leader
10/27/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will host a Key Opinion Leader (KOL) webinar on COVID-19 and its implications for treatment options on Thursday, November 5, 2020 at 10am Eastern Time.
-
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
10/22/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the first two patients have been dosed in an investigator-initiated Phase II clinical trial evaluating Allocetra TM in severe and critical COVID-19 patients. This COVID-19 study is designed as a multi-center, investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to twenty-four COVID-19 patien
-
BioSpace Global Roundup, Oct. 15
10/15/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
10/13/2020
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed investigator-initiated Phase II clinical trial evaluating Allocetra TM in severe and critical COVID-19 patients. The planned COVID-19 study is a multi-center investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to twenty-f
-
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
10/1/2020
Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, reported positive top-line results of an investigator-initiated clinical trial of AllocetraTM in COVID-19 patients in severe/critical condition.
-
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
9/16/2020
Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application covering ALLOCETRATM, the company’s immunotherapy product candidate.
-
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
8/25/2020
Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering ALLOCETRA TM , the company’s immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection, including methods, uses and pharmaceutical compositions. The company expects that this new patent will be